mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Partners

Maxwell Biotech Group promotes effective engagement with all stakeholders of the venture investment market: from business angels to state development institutes.

The Group’s key partners are:

The Russian Venture Company (RVC). RVC is a government fund of funds and a development institute of the Russian Federation, one of Russia's key tools in building its own national innovation system.

MBG also collaborates with the Russian Seed Investment Fund (FPI RVC) and two RVC’s subsidiary funds — Biopharmaceutical Investment Fund (RVC BioFund) and Infrastructure Investment Fund (RVC InfraFund).

The main financial resource of MBG is Maxwell Asset Management, which was founded in 2003 and soon became one of the top Russian companies in the mutual fund investments market. In 2008 Maxwell Asset Management won the tender announced by RVC for the formation and management of the Maxwell Biotech Venture Fund, of a new $100 million fund specializing in investments in the life science sector.

The Skolkovo Foundation is a non-profit organization founded in September 2010 by the Russian government with the objective of accelerating Russia’s transformation from a resource-intensive to an innovation-based economy. To achieve this objective, the Foundation is overseeing the creation of the Skolkovo Innovation Center, composed of more than 1,400 high-tech startups, Skolkovo Technopark, the Skolkovo Institute of Technology (Skoltech) — a new graduate research University established in collaboration with the Massachusetts Institute of Technology — and Skolkovo city, located near Moscow. Together, these entities establish a vibrant ecosystem of technology innovation and entrepreneurship.

The circle of the Group’s partners includes Russian and international biotech and pharmaceutical companies, contract service organizations, research institutes and laboratories.

© Maxwell Biotech Group Ltd.

TOP